Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
29 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 37
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇸🇬 SingaporeOfficialfull/abridged/verification, priority, reference agenciescurrent frameworkLatest observed: 2026-03-13
🇸🇬 SingaporeOfficialdossier screening, 50-day target, evaluation outputcurrent TATLatest observed: 2026-05-05
🇸🇬 SingaporeOfficialHTA, value-based pricing and 2027/2028 company-submission calendarscurrent process; calendar revised 2026-10-08Latest observed: 2026-10-08
🇸🇬 SingaporeOfficialACE/DAC, SDL, MAF, CDL rolescurrent educational factsheetLatest observed: checked live
🇸🇬 SingaporeOfficialtopic selection, evaluation, VBP/RSA, DAC, implementation, monitoring/review, RDFVersion 3.1 Sep 2023Latest observed: linked by current 2026 page
🇸🇬 SingaporeOfficialSDL/MAF list version and institution-specific availabilitylist as of 2026-09-01Latest observed: 2026-08-31
🇸🇬 SingaporeOfficialIndication-specific cancer coverage, subsidy status and claim limitslist/limits as of 2026-09-01Latest observed: 2026-08-31
🇸🇬 SingaporeOfficialsubsidy purpose, residency, means testing, eligibilitycurrent subsidy frameworkLatest observed: 2025-01-02 / 2024-10-26
🇸🇬 SingaporeOfficialsubsidy purpose, residency, means testing, eligibilitycurrent subsidy frameworkLatest observed: 2025-01-02 / 2024-10-26
🇸🇬 SingaporeOfficialPublic procurement, SAP Business Network onboarding and phased invoice requirementsrollout phases from 2026-08-03 / 2026-08-17 / 2027-01Latest observed: 2026-10-14
🇸🇬 SingaporeOfficialpost-approval changes, RMP and utilisation requestscurrent frameworkLatest observed: 2026-03-17/19
🇸🇬 SingaporeOfficialpost-approval changes, RMP and utilisation requestscurrent frameworkLatest observed: 2026-03-17/19
🇸🇬 SingaporeOfficialdiscretionary last-line support after insurance/MediSave2026-01-29Latest observed: 2026-01-29
🇸🇬 SingaporeOfficialregistration boundary and post-market actions2026-04-09Latest observed: 2026-04-09
🇸🇬 SingaporeOfficialPackaging-configuration registration conditions and forthcoming minor-variation consultation2026-09-30Latest observed: 2026-09-30
🇸🇬 SingaporeOfficialPackaging-configuration registration conditions and forthcoming minor-variation consultation2026-09-30Latest observed: 2026-09-30
🇸🇬 SingaporeOfficialElectronic-labelling notification, access, GSL safety information and monitoring conditions2026-06-30Latest observed: 2026-06
🇸🇬 SingaporeOfficialElectronic-labelling notification, access, GSL safety information and monitoring conditions2026-06-30Latest observed: 2026-06
🇸🇬 SingaporeOfficialSupporting role, data suitability and reporting of RWE in HTA2026-01Latest observed: Version 1.0 January 2026
🇸🇬 SingaporeOfficialDesign, data quality, analysis and limits of real-world external controls2026-09Latest observed: Version 1.0 September 2026
🇸🇬 SingaporeOfficialReview-service offer, payment and acceptance, dated fees and limited refunds; separate from funding and price/access agreements.2025-01-07Latest observed: 2025-01-07
🇸🇬 SingaporeOfficialSix-year acquisition budget, patient-estimation methods, net public-institution cost and scenario instructions; identified market-share formula limitations require independent reconciliation.2024-07Latest observed: 2024-07
🇸🇬 SingaporeOfficialACE economic-model cost references and units, no-inflation instruction and exclusion of patient billing use; category descriptions need matching to the intended resource.2026-06Latest observed: 2026-06
🇸🇬 SingaporeOfficialFull company guide v1.6: entry and review process, local clinical evidence, economic reference case, financial impact, agreements and Appendix1 checklist; referenced form bodies remain separate.2024-10Latest observed: 2024-10
🇸🇬 SingaporeOfficialFull v3.1 guide: ACE-led topic selection, evidence and reference case, pricing and implementation, monitoring, RDF and vaccine addenda, and supplementary evidence/RFI annexes; company-led rules and current payment lists remain separate.2023-09Latest observed: 2023-09
🇸🇬 SingaporeOfficialAll nine sections: evaluation/listing scope, diagnostic and clinical pathway, evidence, model/code/costing, regulatory and overseas HTA timing.2024-12-04Latest observed: 2024-12-04
🇸🇬 SingaporeOfficialClinical/economic issue response and factual correction tables, unchanged font, five-page cap, Word return and case-specific deadline.Official link labelled October2023; body undatedLatest observed: Official link labelled October2023
🇸🇬 SingaporeOfficialPublic template terms for price and patient-scope distinctions, supply reporting, reconciliation, continuation and termination; agreed values and redacted formulas remain product-specific.Date not statedLatest observed: Date not stated
🇸🇬 SingaporeOfficialRegistration dossiers, route-specific reference reports, CMC declarations and post-approval variation requirements; external appendices and legislation have separate scope.2026-04Latest observed: 2026-04 guidance; 2026-06-01 CMC declaration requirement
🇸🇬 SingaporeOfficialRegistration dossiers, route-specific reference reports, CMC declarations and post-approval variation requirements; external appendices and legislation have separate scope.2026-04Latest observed: 2026-04 guidance; 2026-06-01 CMC declaration requirement
🇸🇬 SingaporeOfficialWorking-day screening/evaluation targets and stop-clock boundaries; reference targets, not guaranteed dates.2026-04Latest observed: 2026-04
🇸🇬 SingaporeOfficialWorking-day screening/evaluation targets and stop-clock boundaries; reference targets, not guaranteed dates.2026-04Latest observed: 2026-04
🇸🇬 SingaporeOfficialSelected-product concurrent review, pipeline selection, invitation timing, consent, normal fees and non-guaranteed first-HTA target.2026-10-12Latest observed: 2026-10-12
🇸🇬 SingaporeOfficialSelected-product concurrent review, pipeline selection, invitation timing, consent, normal fees and non-guaranteed first-HTA target.2026-10-12Latest observed: 2026-10-12
🇸🇬 SingaporeOfficialSelected-product concurrent review, pipeline selection, invitation timing, consent, normal fees and non-guaranteed first-HTA target.2026-10-12Latest observed: 2026-10-12
🇸🇬 SingaporeOfficialApril1 official acceptance, voluntary initial NDA/GDA/DMF scope and continuation of non-eCTD channels.2026-04-01Latest observed: 2026-05-26
🇸🇬 SingaporeOfficialGuidance version, separate subsidy/claims columns and their implementation dates; individual treatment criteria require product-specific checking.2026-10-05Latest observed: 2026-10-05
For education only — not regulatory, pricing or legal advice.